Effect of Ultrasound-guided Piriformis Muscle Corticosteroid Injection Versus Extracorporeal Shock Wave Therapy for Piriformis Syndrome: a Randomized Control Trial

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Piriformis SyndromeCorticosteroid InjectionExtracorporeal Shockwave TherapyTherapeutic Exercise
Interventions
PROCEDURE

Extracorporeal shockwave therapy (ESWT)

The therapy will be performed with the focused piezoelectric shockwave (F10G4 Richard Wolf GmbH, Germany). The patient will be kept in the hip flexion, adduction and internal rotation position. After sonography-guided localization of the affected muscle and identification of the trigger point by the participant, ultrasound gel is applied to the skin and the applicator couple is placed with an impulse energy flux density of 0.456-0.882 mJ/mm2 for 3500 impulses.

PROCEDURE

Ultrasound-guided piriformis steroid injection

all the participants will receive ultrasound-guided piriformis injection with 10 mg triamcinolone and 1 c.c. 1% lidocaine for one time.

Trial Locations (1)

Unknown

Shin Kong Wu Ho-Su Memorial Hospital, Taipei

All Listed Sponsors
lead

Shin Kong Wu Ho-Su Memorial Hospital

OTHER

NCT04684537 - Effect of Ultrasound-guided Piriformis Muscle Corticosteroid Injection Versus Extracorporeal Shock Wave Therapy for Piriformis Syndrome: a Randomized Control Trial | Biotech Hunter | Biotech Hunter